...
首页> 外文期刊>Frontiers in Pharmacology >Participation of Dopamine D1 and D2 Receptors in the Rapid-Onset Behavioral Sensitization to Modafinil
【24h】

Participation of Dopamine D1 and D2 Receptors in the Rapid-Onset Behavioral Sensitization to Modafinil

机译:多巴胺D1和D2受体参与莫达非尼的快速起效行为敏化。

获取原文
           

摘要

Studies on the abuse potential of modafinil, a psychostimulant-like drug used to treat narcolepsy, are still controversial. While some studies claim no potential for abuse, increasing evidence suggests that modafinil induces abuse-related effects, including rapid-onset behavioral sensitization (i.e., a type of sensitization that develops within hours from the drug priming administration). The rapid-onset sensitization paradigm is a valuable tool to study the neuroplastic changes that occur quickly after drug administration, and shares neuroadaptations with drug abuse in humans. However, the mechanisms involved in the rapid-onset behavioral sensitization induced by modafinil are uncertain. Our aim was to investigate the possible involvement of dopamine D1 and D2 receptors on acute modafinil-induced hyperlocomotion and on the induction and expression of rapid-onset behavioral sensitization induced by modafinil in male Swiss mice. Treatment with the D1 receptor antagonist SCH 23390 or the D2 receptor antagonist sulpiride attenuated the acute modafinil-induced hyperlocomotion in a dose-dependent manner. Pretreatment with either antagonist before the priming injection of modafinil prevented the development of sensitization in response to a modafinil challenge 4 h later. However, only SCH 23390 decreased the expression of modafinil-induced rapid-onset behavioral sensitization. Taken together, the present findings provide evidence of the participation of D1 and D2 receptors on the development of rapid-onset behavioral sensitization to modafinil, and point to a prominent role of D1 receptors on the expression of this phenomenon.
机译:关于莫达非尼(一种用于治疗发作性睡病的精神刺激药)的滥用潜力的研究仍存在争议。尽管一些研究声称没有滥用的潜力,但越来越多的证据表明莫达非尼会引起与滥用有关的影响,包括快速发作的行为致敏作用(即一种从药物启动给药后数小时内产生的致敏作用)。快速发作的敏化范例是研究药物给药后迅速发生的神经塑性变化的有价值的工具,并且与人类药物滥用具有神经适应性。然而,莫达非尼引起的快速发作的行为致敏的机制尚不确定。我们的目的是研究多巴胺D1和D2受体可能与莫达非尼诱导的急性运动过度以及莫达非尼在雄性瑞士小鼠中诱导和表达的快速发作的行为致敏有关。 D1受体拮抗剂SCH 23390或D2受体拮抗剂舒必利治疗以剂量依赖性方式减弱了莫达非尼引起的急性运动过度。在初次注射莫达非尼之前用任何一种拮抗剂进行预处理均可以防止在4小时后对莫达非尼激发产生敏化作用。但是,只有SCH 23390降低了莫达非尼诱导的快速发作行为敏化的表达。综上所述,本发明的发现提供了D1和D2受体参与对莫达非尼的快速发作的行为敏化发展的证据,并指出了D1受体在该现象的表达上的重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号